Patients with non-valvular atrial fibrillation and those at risk of venous thromboembolism are the primary beneficiaries of DOAC therapy. These drugs are also beneficial for patients who have experienced adverse reactions to warfarin or have difficulty maintaining therapeutic INR levels.
